Fevertree Drinks (AIM:FEVR) said it is trading in line with expectations, in a statement ahead of today's annual general meeting.
The tonic and mixer maker forecasts low single-digit revenue growth and an adjusted EBITDA margin of around 12% for its financial year.
In the US, Fevertree noted strong momentum with brand performance described as "well ahead of the competition".
The American operation is beginning to see progress in its partnership with Molson Coors, with the brands currently working through the key months of transition.
The British performance sees the firm retaining its "number one position", capturing growth in both alcoholic and non-alcoholic settings, whilst in Australia, Fevertree highlighted that in-country production has started.
It meanwhile flagged 'solid performances' in the Netherlands and France, but Germany remains softer.
As part of its £100 million share buyback announced earlier in 2025, Fevertree has returned around £42.5 million to shareholders to date.
"The group's capital allocation framework remains unchanged," Fevertree said.
"We intend to retain sufficient cash for investment opportunities, primarily in operational expenditure, including increased marketing spend in growth regions.
"We are also vigilant regarding M&A opportunities that would further assist with the delivery of our strategy."